Neuroendocrine Tumors

Latest News

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.
BXCL701 Earns FDA FTD in Small Cell Neuroendocrine Prostate Cancer

February 12th 2024

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Data from the phase 3 NETTER-2 trial support the frontline use of Lutetium Lu 77 dotatate well-differentiated gastroenteropancreatic neuroendocrine tumors.
Radioligand Therapy Significantly Improves PFS in GEP-NET Population

January 20th 2024

177Lu-PNT2003 is a generic version of lutetium Lu 177 dotatate, which is used to treat somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.
FDA Accepts Abbreviated NDA for 177Lu-PNT2003 in SSTR+ GEP-NETs

January 12th 2024

Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.
Cabozantinib Improves PFS Vs Placebo in Advanced Neuroenocrine Tumors

October 22nd 2023

Over half of all patients with small cell neuroendocrine prostate cancer treated with BXCL701 and pembrolizumab were alive at 1 year in a phase 2 trial.
BXCL701 Combo May Improve OS in Small Cell Neuroendocrine Prostate Cancer

October 10th 2023

Video Interviews

More News